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In more than 50% of cancers, p53, a tumor suppressor gene involved cell cycle arrest and 
apoptosis, has been seen to be heavily mutated making it an important gene to study. There are 
several studies on p53 and its role in cancer, but they ignore the impact of genetic background. 
Past studies have shown that genetic background can have a significant effect on the phenotypic 
consequences of cancer driver mutations, however, all these studies are carried out in a 
heterogeneous environment. The goal of my study was to utilize the CRISPR Cas 9 system to 
create a loss of function mutation in the p53 gene in a well characterized human cell line 
(HEYA8F8) and to evaluate the impact of this mutation on cell growth and apoptotic function in 
identical genetic backgrounds. The resulting mutation was a deletion in codons 33-36 of exon 4 
which decreased the length of the protein from 393 to 389 amino acids. Using the cell lines with 
the specified deletion, growth rates over 96 hours were compared, which resulted in higher cell 
counts for the mutant in comparison to the wildtype. Assay for drug sensitivity using cisplatin, 
the standard of care for many cancers, showed that mutant cell lines had decreased apoptotic 
function (higher cell viability) in comparison to the wild type. The overall results demonstrated 
that mutations in p53 increase cell viability when treated with chemotherapy and an increase in 
cell proliferation. We believe that the cell lines with the loss of function mutations in p53 
generated will provide an ideal experimental set up to study how the genetic background can 






CHAPTER 1.  INTRODUCTION 
Cancer, a collection of diseases caused by malfunctioning cells, is the second leading 
cause of death worldwide (WHO, “Cancer”, 2020; NCI, “What is Cancer?”, 2015). Cancer arises 
from genetic mutations in cells and can occur almost anywhere in the body. The origin point of 
cancer cells helps distinguish different cancers from one another (NCI, “What is Cancer?”, 
2015). Even similar categories of cancers can vastly differ making it a heterogeneous disease. 
Globally, one in six deaths is due to cancer; thus, the diseases' research is relevant to our lives.  
A major question in cancer research is differentiating cancer cells from normal cells. In 
2011, Hanahan and Weinberg proposed a list of ten hallmarks used to characterize cancer (2011). 
They defined a hallmark as “distinctive and complementary capabilities that enable cancer 
growth and metastatic dissemination.” These ten hallmarks form an organizing principle for 
understanding cancer as a disease. 
These hallmarks help categorize cancer driver genes (CDGs): genes that are said to 
promote tumor growth (Bailey et al., 2018). Cancer driver mutations are said to give an 
advantage to cancerous cells, and it is suggested that 5-7 driver mutations are required for the 
formation of most cancers (Pecorino, 2016). One common CDG that is mutated in a majority of 
cancers is the p53 gene (Bailey et al., 2018). Upon observation, this gene is involved with two 
cancer hallmarks: sustaining proliferative signaling and resisting cell death (Rivlin et al., 2011).  
The p53 gene is a tumor suppressor (Zilfou, 2009). Upon activation, p53 will hinder the 
formation of cancer cells. The gene works as a transcriptional regulator for growth arrest 
(sustaining proliferative signaling) and apoptosis (resisting cell death). More than 75% of 
mutations in cancers is due to an error in the p53 protein; hence, it is one of the most widely 
studied genes in the human genome (Muller & Vousden, 2013).  
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Classified as the “Guardian of the Genome,” p53 is considered a major part of tumor 
suppressive mechanisms (Yue et al., 2017). Located on chromosome 17, p53 encodes for a 393 
amino acid long protein. This protein can be divided into four domains, each with its own 
function ranging from transactivation to DNA binding. Each domain has certain areas that are 
heavily mutated in a majority of cancer cases, defined as mutational hotspots (Hsu, 1991). The 
p53 gene is involved with transcriptional regulation with downstream targets, and its activity is 
regulated at the protein level rather than the gene expression level. In healthy and non-stressed 
cells, p53 protein levels are low due to its negative feedback loop with MDM2, a negative 
regulator of p53 (Harris, 2005). MDM2 works by attaching ubiquitin to p53 which marks it as a 
target to be degraded, leading to the overall decrease in p53 expression. In turn, p53 is a 
transcriptional activator for MDM2, creating a balanced system between these two proteins.  
Under stress conditions, the most common being DNA damage, p53 is activated and 
stabilized through phosphorylation, acetylation, and methylation (Yue et al., 2017). Stabilizing 
p53 alters the structure to prevent it from binding to MDM2 and from being degraded.  
The activation of p53 leads to the halting of the cell cycle or the activation of the 
apoptotic pathway (Levine, 1997). The decision of which pathway is taken is determined by the 
extent of DNA damage and the cellular stresses it releases (Harris & Levine, 2005). This 
decision makes p53 a gatekeeper for cells in the body.  
All cells in the body undergo a process of growth through the cell cycle. In the cell cycle, 
there are several checkpoints in place to prevent irregular cells from duplicating. p53 is involved 
with two checkpoints in the S and M phases (Harris & Levine, 2005). Under low levels of DNA 
damage, p53 will activate its cell cycle arrest pathway. As a result, p53 will interact with proteins 
such as p21, a cyclin dependent kinase inhibitor. When active, p21 will inhibit cyclin dependent 
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kinases (CDKs) that are specifically involved with driving the cell into the next phase of the cell 
cycle. p21’s interaction will halt the cell cycle in the S and M phase. While the cell cycle is 
halted, DNA repair mechanisms will be activated to fix the damage (Vugt, Bràs, & Medema, 
2005). Once the damage is fixed, the cell will continue through the cell cycle as planned.  
 However, there are some instances in which the damage in the cell is too great and repair 
is impossible. When this occurs, apoptosis, or programmed cell death, is activated to remove the 
old and damaged cells (Pecorino, 2016). This process is highly conserved across organisms and 
is completed without damaging the surrounding cells. Apoptosis occurs with a set of signals that 
activates a signaling cascade, causing the cells’ contents to shrink and to undergo phagocytosis, 
the engulfing of material for disposal. 
p53 will activate the apoptotic pathway, or cell programmed death. In normal cells, a 
stress signal such as DNA damage will induce the apoptotic pathway (Pecorino, 2016). Once 
DNA damage is recognized, p53 is activated and stabilized. Functional p53 will then induce the 
expression of genes that encode for receptors that activate the caspase cascade such as Bax 
protein. Bax then activates the caspase cascade, which starts the shrinking of cell content and 
formation of apoptotic bodies to undergo phagocytosis. This cascading process leaves only 
healthy cells.  
 These pathways activated by p53 demonstrate its gatekeeper functions as a tumor 
suppressor (Zilfou, 2009). Both arresting the cell cycle and activating the apoptotic pathway are 
options that lead to cellular and genetic stability by ensuring that cells are fixed or killed if 
damaged beyond repair. Since p53 is such an important gatekeeper, it is unsurprising that p53 is 
highly mutated in cancer. In cancer, the p53 pathway is inhibited, which allows cancer cells to 
grow uncontrollably. This mutation prevents p53’s ability to examine cells for abnormalities, 
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thereby preventing activation and proper function. Mutant p53 will not activate proteins such as 
p21, which inhibits cyclin-dependent kinases (CDKs) that are important for cell cycle 
continuation (Pecorino, 2016). Since CDKs are not inhibited, cell growth will continue despite 
DNA damage. In apoptosis, a mutation in p53 prevents the activation of the apoptotic pathway 
by not activating Bax. Since the Bax protein activates the caspase cascade in apoptosis, the 
removal of Bax allows for cancerous cells to avoid cell death despite being severely damaged. 
Even though cellular stress occurs, the mutation in p53 allows cancer cells to form and persist.  
While cancer driver mutations such as p53 have been widely studied, understanding of 
how cancer forms is more complicated than just mutations in certain genes. In reality, several 
factors including mutations in cancer driver genes may increase the chance of cancer (Mittal, 
2015). The interactions of other proteins, especially those upstream from p53, can impact cancer 
formation. These interactions and other genes that are not of special interest in a study are called 
genetic background. Studies have shown that genetic background and cancer driver genes can 
increase the chances of cancer (Balmain, 2002). Genetic background can have a significant effect 
on the phenotypic consequences of cancer driver mutations. Simply put, an organism’s genetic 
background can impact how cancer forms and impacts the ability of cancer to gain functions that 
assist in the survival of cancer. For instance, Donehower et al. found that mice with different 
genetic backgrounds but infected with the same cancer cells have different rates of tumorigenesis 
(1993). Despite the same mutation and infection of cancer driver cells, the genetic background 
had an influence on the tumorigenesis of the different mice. A newer study called “The 
evolutionary history of 2,658 cancers” determined that early oncogenesis is limited to the cancer 
driver mutations (Gerstung et al., 2020). However, as time passes, mutations will occur in the 
genetic background of the cell. These mutations are suggested to enhance the effect of the cancer 
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driver mutations and are shown to shape how cancer evolves. These studies lead to the 
possibility that mutations in cancer driver genes do not create the full phenotypic effect of cancer 
and questions how much a mutation in a cancer driver gene affects cancer.  
While there are several studies on the function of p53 in cancer, most of them only 
examine genes affected by p53 and ignore genetic background. Studies of p53 in a 
heterogeneous genetic background do give meaningful results, however heterogeneous 
background prevents the understanding of how genetic background impact cancer phenotypes. 
For instance, a study in different cell types with the same loss of function (LOF) mutation in p53 
found some unexplained gain of function activities in terms of cell growth and apoptosis (Bossi 
et al., 2005). While the study was done with the same mutation, the different cell lines meant the 
comparison was between different genetic backgrounds. This study suggests that genetic 
background may lead to gain of function activities in cancer cells. Another more recent study 
examined the role of p53 isoforms, or p53 protein variants, in renal cell cancer prognosis 
(Florijan et al., 2019). This study compared p53 isoforms between different patients of renal cell 
cancer which demonstrated that p53 isoforms are differentially expressed depending on 
mutational status. While these studies have given us a better understanding of p53 and its 
function, these comparisons do not account for genetic background.  
The goal of this study was to utilize the CRISPR-Cas9 system to create a loss of function 
(LOF) mutation in the p53 gene in a well characterized human cell line (HeyA8F8) and to 
evaluate the impact of this mutation on cell growth and apoptotic function in identical genetic 
backgrounds. The HeyA8F8 cell line contains functional “wildtype” p53 alleles, making it an 
ideal choice. To accomplish this study, the following specific aims were created. The first was to 
employ the CRISPR-Cas9 system to create deletion mutations in a functionally significant region 
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of the p53 gene in the HeyA8F8 cell line. Then the molecular impact (protein and RNA levels) 
of p53 deletion mutations were determined. Finally, growth rates and relative apoptotic function 
between the wildtype p53 and p53 deletion mutants were compared. We hypothesized that a 
deletion mutation in p53 will show decreased expression as well as impact growth function and 
apoptotic function. The expectation of this study is to further emphasize the impact of a mutation 
on p53 in cancer cells as well as to provide an experimental cell line that can be used in the 
future to study the development of genetic background changes that occur in cells subsequent to 





CHAPTER 2.  MATERIAL AND METHODS 
2.1      Determining CRISPR-Cas9 Target Location 
Functionally significant TP53 mutations are distributed in all coding exons of the TP53 
gene, with a strong predominance in exon 4-9 (Rivlin, Brosh, Oren, & Rotter, 2011). Each exon 
has certain points that are mutational hotspots, and these exons are seen to be heavily mutated in 
cancer (Hsu, 1991). While a majority of mutations have been seen in the DNA binding domain, 
recent research has found a high prevalence of mutations in exon 4 since it lies close to the 
central region of the gene involved in DNA specific binding (Shepherd, et al., 2000). Since exon 
4 is part of the transactivating domain, which is a part of p53 that interacts with other proteins, 
focus was specifically directed to the beginning portion of exon 4. This portion of exon 4 
contains a few sites where it interacts with other proteins, specifically serine 33. Past studies of 
serine 33 have identified it as a phosphorylation site. Serine 33 interacts with other protein 
kinases (a kinase enzyme that modifies other proteins by chemically adding phosphate groups) 
such as p38. p38, a stress-activated protein kinase, helps mediate apoptosis and phosphorylates 
p53 at serine 33. In a study by Yogosawa and Yoshida, inhibition of p38 showed a reduction in 
phosphorylation of p53 at serine 33 (2018). This reduction in phosphorylation led to a reduction 
of apoptosis, suggesting that p38 plays a role in p53 mediated apoptosis. Another study showed 
that cyclin-dependent kinase 9 (CDK9), a protein kinase involved in the regulation of 
transcription (DNA to RNA), was also found to phosphorylate p53 on serine 33 (Radhakrishnan 
et al., 2006). CDK9 is found to be a component of the positive transcription elongation factor 
(pTEFB) and also interacts with RNA polymerase II, which expresses genes involved with 
proliferation and cell survival. While these papers do not give precise biological reasons or roles 
for phosphorylation, they suggest that serine 33 is important for apoptosis and cell proliferation. 
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In addition to the functional significance of this area, according to Synthego, who provided the 
guide RNAs for the CRISPR-Cas9 system, this location was specifically chosen for its high on-
target score and low off-target homology. The specificity and the functional significance 
suggested that this attack location would cause a unique deletion in the p53 gene.  
2.2      Cell Lines 
Even though p53 is seen mutated in several cancers, our study was based on the 
HeyA8F8 cell line, a derivative of the HeyA8 cells (Pellicciotta et al., 2013). The HeyA8F8 cell 
line was altered to include a luciferase enzyme that allows for non-surgery bioluminescence 
imaging in mice for pre-clinical studies (Satpathy et al., 2016).  
All cells were maintained in a growth medium consisting of RPMI 1640 (cell culture 
media), fetal bovine serum, and antibiotic antimycotic solution, all from Corning Inc. Cells were 
grown in single layer cultures and were kept in an incubator at 37 degrees with 5% carbon 
dioxide. 
2.3      Mutated Cell Lines 
The HeyA8F8 cell line was genetically edited to create a functionally significant p53 
mutation. Since the guide RNAs provided had a high on-target score and a low off-target 
homology, it was believed to be specific in its mutation. p53 was altered to create a deletion 
mutation in exon 4. Exon 4 was chosen due to its high prevalence of mutations in soft tissue 
sarcomas and its lack of knowledge (Das et al., 2007).  
To create this deletion, CRISPR-Cas 9 was used. Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR) are DNA sequences that are found in the genome of prokaryotic 
organisms and were first discovered in Escherichia coli (Ratan et al., 2018). Cas9 (CRISPR 
associated protein 9) is an endonuclease, an enzyme that cleaves both strands of DNA. To 
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determine cleavage location, guide sequences find a complementary match in the targeted DNA. 
This method of cleavage with a specific guide led scientists to test if this system could be 
implemented as a genome editing tool. The CRISPR-Cas9 system is made up of two parts, the 
Cas9 enzyme and the guide RNA sequence. The system works by inserting the CRISPR-Cas9 
system into a cell with a specific guide RNA. In addition to the guide RNA, the protospacer 
adjacent motif (PAM) with 5’-NGG-3’ sequence on the targeted DNA is required for cleavage 
(Takara, 2020). To initiate gene editing, the guide RNA will find a matching sequence and bind. 
This will activate the Cas9 enzyme to cleave the DNA a few base pairs upstream of the PAM 
sequence causing a double stranded break. There are two methods of DNA repair. One option is 
to use homology directed repair, which requires the use of a template. The template will provide 
a strand that will allow for repair of the gene. In this option, a template strand can be given a 
specific change or insertion that causes a change in the DNA sequence. The other option is non-
homologous end joining. This method works by DNA attempting to fix the break without a 
template. Since there is a double stranded break, nucleotides near the break will be removed, and 
then the two strands will be glued together. In our experiment, we used CRISPR-Cas9 to cause a 
double stranded break in exon 4 that was fixed with non-homologous end joining, since no 
template sequence was provided. Using the protocol and guide RNAs from Synthego, the 
mutated cells were created using the Synthego CRISPR-Cas9 Gene Knockout Kit (2019). 
According to Synthego, this kit guarantees that at least 50% of alleles in the pool of cells should 
have been edited. Four different guide RNAs were used in separate experiments to maximize p53 
knockout. The guide RNAs were set to bind at exon 4 with the PAM sequence located in codon 
33 and 34 (Figure 1). Each different guide RNA was used in a separate experiment, increasing 
the possibility of creating cells with a LOF mutation in p53. Once cells were potentially mutated 
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with CRISPR-Cas9, they were examined using an Invitrogen Detection Kit to detect cleavage. 
This kit shows if the CRISPR-Cas9 system worked and gives an estimation of the system’s 
efficiency.  
 
Figure 1: Guide RNAs used to target exon 4 of p53. Four guide RNAs from Synthego are shown in blue 
with the PAM sequence in green. Each gRNA met with Synthego’s design criteria of early coding exon, 
common across all transcripts, high on-target score and low off target homology (Synthego, 2019). All 
four gRNAs were used in four different experiments of editing HeyA8F8 cells.  
 
2.4      Single Cell Colonies and Mutated Strains 
Once the detection kit showed results of cleavage, the mutated cell solutions were 
isolated to make single cell colonies. To create the different cell lines, clonal isolation was done. 
This was done by diluting the cells to a solution of 0.5-0.8 cells per 100uL. Then 100uL of the 
total solution was added to each well on a 96 well plate in the hope that only one cell would be in 
each well. From there, one single cell would divide and create its own colony. Once cells in a 
well seemed to be confluent, covering a majority of the cell surface, the cells were transferred to 
a larger cell plate until they were confluent enough to be put into a t-25 flask. Incubation of 
single cells to create new cell lines was only 24% successful. From successful colonies, we 
decided to focus on the following mutant strains: G1C4, G2C4, G3B2, G3C11, and G4F12.  
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2.5      DNA Extraction 
After growing the single cell clones, their DNA was extracted and sent to be sequenced 
by Eurofins Genomics. While this did give sequencing results, this method did not provide clean 
sequencing results, suggesting single cell clones were not homozygous. The alternative method 
was to clone PCR product into a plasmid to obtain the sequence. Using PCR primers created to 
flank the targeted site in exon 4, the extracted DNA underwent PCR and the PCR product was 
then ligated into a plasmid that contained an antibiotic resistance aspect. This plasmid was then 
transfected into E. coli bacteria. After transfection, bacteria was plated and then treated with 
antibiotics. Since bacteria can only have one plasmid, only the bacteria with the plasmid that 
contains antibiotic resistance will survive. In addition to false positives, the PCR product was 
inserted into the LacZ gene, which normally gives bacteria a blue color. As a result, the bacteria 
with the plasmid and PCR product should be white colored bacteria. The white colored bacteria 
was then extracted and its DNA was isolated. The isolated product with primers in the genomic 
DNA that flanked the target site was sent to be sequenced at Eurofins Genomics. If all the 
sequences from the different populations had the same deletion, then the cell strain would be a 
homozygous population with a mutation in both alleles. However, if there were some sequences 
with deletion as well as some without deletions, this suggests that it was a heterozygous 
population and that the single cell colony was not correct. The results of the sequencing gave seq 
files of around 500 base pairs that could be aligned.  
2.6      Alignment and Protein Translation 
Using the obtained seq files, DNA sequences were aligned using Clustal Omega, which is 
a new multiple sequence alignment program that uses seeded guide trees and HMM profile-
profile techniques to generate alignments between three or more sequences (Sievers et al., 2011). 
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The wildtype sequence was the HeyA8F8 cell line, and the mutant cell lines were those created 
using the CRISPR-Cas9 system. In addition, p53 sequence from the International Agency for 
Research on Cancer (IARC) were used as reference. The DNA sequences were then entered into 
ExPASy Translate tool which gave the protein sequence (Artimo, 2012). Final alignment in the 
5’ to 3’ direction showed the primer sites, splice sites (pairs of bases that define the border 
between the intronic and exonic sequence for removal of introns) and exon regions with 
corresponding amino acids below with codon numbering. From the alignment file, one mutant 
strain (G3B2) was chosen to further study.  
2.7      Western Blot 
To determine the molecular impact of the deletion in p53, protein expression was 
measured. This was done using a Western Blot analysis. Cell lines were lysed in cell lysis buffer 
(CelLytic MT, Sigma) that contained protease inhibitors (Sigma) and were sonicated briefly. The 
sonicated precleared lysates containing proteins were then boiled in 4X sample buffer (Bio-Rad) 
and 2-mercaptoethanol. A Bio-Rad polyacrylamide gradient gel was loaded with the final 
solution. Gels were then transferred to a nitrocellulose paper and were blocked with 5% fetal 
bovine serum albumin in 10nM tris-buffered saline, pH 7.5, plus 1% Tween 20 (TBST, BioRad), 
for 1 hour at room temperature. The blots were probed with the following antibodies: p53 
monoclonal antibody (Novousbio cat. no.NB200-103SS) and B-actin monoclonal antibody 
(Sigma, cat no 5441) diluted in 5% BSA in TBST overnight, with shaking at 4 °C. After 
incubation with the corresponding anti-mouse-horseradish peroxidase-conjugated secondary 
antibodies (Thermo Scientific Cat # 31430), the Western blots were developed by using the 
chemiluminescence technique (Pierce) according to the manufacturer's instructions. ImageJ was 
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used to quantify the protein expression values from the gel. Three different quantification 
methods of pixel density were used to compare statistical significance.  
2.8      RNA Structure 
 To determine the possible effect of the deletion on RNA structure, RNAfold was used to 
predict the secondary structure using the Minimum Free Energy (MFE) method (2019). 
Prediction software focused on the 500 base pairs that flanked the deletion region. Imaging and 
free energy values were taken and compared. Free energy values were calculated based on the 
paper by Zuker and Stiegler (1981).  
2.9      RT-PCR 
In addition to testing protein levels, we conducted real-time PCR with cyber green 
fluorescent dye to determine RNA expression levels. PCR data was collected following the Bio-
Rad protocol with six replicates per cell line, 3 for the target gene and 3 for the reference gene. 
GAPDH was used as the reference gene. The obtained data values were CT values, which is the 
number of cycles at which the fluorescent signal of the reaction crosses the threshold. Using the 
BioRad protocol for relative quantification between the target and reference as well as 
normalization of the data to the wildtype, fold expression was achieved. The fold expression was 
then averaged between the three replicates and standard error was found.  
2.10      Growth Study Protocol 
After identifying the molecular impact of the mutated cell lines, the growth rate of the 
mutant was compared to the wildtype. This was done by plating a number of cells and counting 
the cells at 24, 48, 72, and 96 hours. To examine growth rate, 100,000 cells per well were plated 
into a 12 well plate. Each plate was for one cell line and was divided by different time points. 
Each time point had 3 replicates. Cells adhered to the bottom of the flask. Thus, counting the 
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number of cells required resuspension of the cells. This was done by first washing the cells in 
PBS, using trypsin to detach the cells, and neutralizing the trypsin with growth medium. The 
cells were then centrifuged down and the liquid was aspirated, leaving a pellet of cells at the 
bottom of the tube. Cells were resuspended in 3-5ml of PBS to add to a hemocytometer for 
counting. Using both sides of the hemocytometer, the average for each section was taken and 
then multiplied by 10^4 to get the total number of cells per volume of PBS. The equation 
C1V1=C2V2 was then used as normalization to determine the number of cells per 1ml from the 
counted stock solution. The average of all replicates was then taken to give the number of cells 
for each 24 hour time point. This average was then graphed and standard error was calculated.  
2.11      Cell Viability Assay 
To test apoptotic function, cell viability under chemotherapy was completed. The 
standard of care for many cancers is Cisplatin, a platinum based drug that targets DNA in cells 
causing DNA damage (Dasari & Tchounwou, 2014). The hope is that Cisplatin will cause 
extreme DNA damage inducing apoptosis of the cell. Since DNA damage also activates p53, 
treating cell lines with cisplatin should demonstrate how this mutation impacts cell viability. The 
Cisplatin concentrations used were 0M, 1nM, 100nm, 1um, 10um, and 50um. Cisplatin 
concentrations were created by diluting a 2.67M stock solution. To test apoptotic function, a 
Sigma In Vitro Toxicology Assay Kit that is Resazurin Based was used. Resazurin is a blue 
fluorogenic dye that, in the presence of enzymes in viable cells, will change to create a red -
fluorescence that can be detected spectrophotometrically in a BioTek Gen5 plate reader (O’Brien 
et al., 2003). Measurements are taken at time zero and every 30 minutes until all wells show a 
change in color. In a 96 well plate, 3,000 cells of the wildtype and mutant were plated in each 
well with 5 replicates for each concentration. 24 hours after plating, the media were removed 
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from each well and respective cisplatin concentrations were added to each well. 48 hours after 
adding the cisplatin medium, they were removed and the dye solution was added. The dye 
solution consisted of 10% of dye stock solution and 90% of cell culture media. Each well got 
100uL of dye solution. The BioTek Gen5 plate reader gave absorbance values which averaged 
across all replicates and then were normalized to the 0M concentration value for each cell line. 
The normalized values were then multiplied by 100 to obtain percent values. Standard error was 
calculated across all replicates for each treatment and cell line. 
2.12      Statistical Analysis 
Determining statistically significant results between the wildtype and mutant cell lines in 
all experiments was done using a two-sample equal variance, one-tailed student’s t-test. A p-
value less than 0.05 was considered to be significant. Additional star markings indicated higher 
significance levels.  
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CHAPTER 3.  RESULTS AND DISCUSSION 
The goal of this study was to determine if a LOF mutation in p53 created by CRISPR-
Cas9 to ensure identical genetic background demonstrated phenotypical differences in terms of 
cell growth and apoptosis. The overall results showed that a deletion in exon 4 encompassing the 
serine 33 phosphorylation site was consistent with previous findings in heterogeneous 
backgrounds — that this mutant is functionally significant.  
3.1      Creation of Successful Strain with p53 Mutation through CRISPR-Cas9 (Aim 1) 
To create the genetically identical mutants, we employed the CRISPR-Cas9 system to 
specifically target exon 4 of p53. Out of the colonies that grew successfully, we focused on 
G1C4, G2C4, G3B2, G3C11 and G4F12.   
After DNA sequencing, we used Clustal Omega to align the five mutant strains, the 
HeyA8F8 wildtype, and IARC p53 reference sequence. Alignment showed mutant G2C4, G3B2 
and G3C11 had a 12-nucleotide deletion in exon 4, while mutant G1C4 showed no difference 




Sequencing and alignment of G4F12 was inconsistent, suggesting that the starting colony 
solution contained more than one cell or that the mutation created was not homozygous. Since 
mutants G2C4, G3B2 and G3C11 had the same alignment and deletion, they were consolidated 
Figure 2: Alignment of mutant cell lines at CRISPR-Cas9 targeted site. Using Clustal Omega, all 
mutant cell lines were aligned to show possible mutations in target site of exon 4. Red indicates exon 4, 
grey highlights indicates splice sites, and stars indicate a consensus among all cell lines. Reference 
sequence was taken from IARC. G1C4, G2C4, G3B2 and G3C11 were single cell colonies grown after 
being edited with Synthego CRISPR-Cas9. 
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into one sequence file and renamed mutant. The wildtype, mutant and reference sequence were 
then all aligned and translated to include amino acids (Figure 3).  
 
Figure 3: Full DNA alignment flanking target site with amino acid sequence. Sequences from Eurofins Genomics 
were aligned using Clustal Omega. Alignment is shown in the 5’ to the 3’ direction with the exonic regions underlined 
and primers and splice sites marked. Stars on the bottom are present where there is a consensus among all 
sequences. Amino acid sequence was translated from DNA sequence using ExPASY tool. Since mutant cell lines G2C4, 
G3B2, and G3C11 had the same deletion, a new sequence file labeled Mutant was used to represent all cell lines.   
5’ End  
Wildtype  GTGGATCCATTGGAAGGGCAGGCCCACCACCCCGACCCCAACCCCAGCCCCCTAGCAGAGACCTGTGGGAAGCGAAAATTCCATGGGACTGACT 
Mutant        GTGGATCCATTGGAAGGGCAGGCCCACCACCCCGACCCCAACCCCAGCCCCCTAGCAGAGACCTGTGGGAAGCGAAAATTCCATGGGACTGACT  
tp53_reference  GTGGATCCATTGGAAGGGCAGGCCCACCACCCCAACCCCAACCCCAGCCCCCTAGCAGAGACCTGTGGGAAGCGAAAATTCCATGGGACTGACT   
                       ********************************* ************************************************************  
                 
               26  27  28  29  30  31  32   
Wildtype    TTCTGCTCTTGTCTTTCAG A CTT CCT GAA AAC AAC GTT CTG GTAAGGGCAAGGGTTGGGC 
Wildtype AA                                   L   P   E   N   N   V   L 
Mutant     TTCTGCTCTTGTCTTTCAG A CTT CCT GAA AAC AAC GTT CTG GTAAGGGCAAGGGTTGGGC 
Mutant AA                                     L   P   E   N   N   V   L 
tp53_reference    TTCTGCTCTTGTCTTTCAG A CTT CCT GAA AAC AAC GTT CTG GTAAGGGCAAGGGTTGGGC 
tp53_reference AA                             L   P   E   N   N   V   L 
                     ******************* * *** *** *** *** *** *** *** ******************* 
 
Wildtype  TGGGGACCTGGAGG----------------GCTGGGGGGCTGGGGGGCTGAGGACCTGGT 
Mutant     TGGGGACCTGGAGG----------------GCTGGGGGGCTGGGGGGCTGAGGACCTGGT 
tp53_reference    tggggacctggagggctggggacctggagggctggggggctggggggctgAGGACCTGGT  
                  **************                ****************************** 
 
    33  34  35  36  37  38  39  40  41  42  43 
Wildtype    CCTCTGACTGCTCTTTTCACCCATCTACAG TCC CCC TTG CCG TCC CAA GCA ATG GAT GAT TTG 
Wildtype AA                 S   P   L   P   S   Q   A   M   D   D   L                     
Mutant     CCTCTGACTGCTCTTTTCACCCATCTACAG --- --- --- --- TCC CAA GCA ATG GAT GAT TTG 
Mutant AA                                        S   Q   A   M   D   D   L                     
tp53_reference    CCTCTGACTGCTCTTTTCACCCATCTACAG TCC CCC TTG CCG TCC CAA GCA ATG GAT GAT TTG  
tp53_reference AA                 S   P   L   P   S   Q   A   M   D   D   L                     
   ******************************                 *** *** *** *** *** *** ***                  
 
 
   44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64    
Wildtype  ATG CTG TCC CCG GAC GAT ATT GAA CAA TGG TTC ACT GAA GAC CCA GGT CCA GAT GAA GCT CCC  
Wildtype AA   M   L   S   P   D   D   I   E   Q   W   F   T   E   D   P   G   P   D   E   A   P 
Mutant            ATG CTG TCC CCG GAC GAT ATT GAA CAA TGG TTC ACT GAA GAC CCA GGT CCA GAT GAA GCT CCC  
Mutant AA   M   L   S   P   D   D   I   E   Q   W   F   T   E   D   P   G   P   D   E   A   P 
tp53_reference    ATG CTG TCC CCG GAC GAT ATT GAA CAA TGG TTC ACT GAA GAC CCA GGT CCA GAT GAA GCT CCC  
tp53_reference AA  M   L   S   P   D   D   I   E   Q   W   F   T   E   D   P   G   P   D   E   A   P 
                  *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** 
 
 
   65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85   
Wildtype    AGA ATG CCA GAG GCT GCT CCC CGC GTG GCC CCT GCA CCA GCA GCT CCT ACA CCG GCG GCC CCT 
Wildtype AA   R   M   P   E   A   A   P   R   V   A   P   A   P   A   A   P   T   P   A   A   P  
Mutant      AGA ATG CCA GAG GCT GCT CCC CGC GTG GCC CCT GCA CCA GCA GCT CCT ACA CCG GCG GCC CCT 
Mutant AA   R   M   P   E   A   A   P   R   V   A   P   A   P   A   A   P   T   P   A   A   P 
tp53_reference    AGA ATG CCA GAG GCT GCT CCC CCC GTG GCC CCT GCA CCA GCA GCT CCT ACA CCG GCG GCC CCT 
tp53_reference AA  R   M   P   E   A   A   P   P   V   A   P   A   P   A   A   P   T   P   A   A   P 
     *** *** *** *** *** *** *** * * *** *** *** *** *** *** *** *** *** *** *** *** *** 
 
 
   86  87  88  89  90  91  92  93  94  95  96  97  98  99  100 101 102 103 104 105 106    
Wildtype  GCA CCA GCC CCC TCC TGG CCC CTG TCA TCT TCT GTC CCT TCC CAG AAA ACC TAC CAG GGC AGC 
Wildtype AA   A   P   A   P   S   W   P   L    S   S   S   V   P   S   Q   K   T   Y   Q   G   S  
Mutant   GCA CCA GCC CCC TCC TGG CCC CTG TCA TCT TCT GTC CCT TCC CAG AAA ACC TAC CAG GGC AGC 
Mutant AA   A   P   A   P   S   W   P   L    S   S   S   V   P   S   Q   K   T   Y   Q   G   S  
tp53_reference  GCA CCA GCC CCC TCC TGG CCC CTG TCA TCT TCT GTC CCT TCC CAG AAA ACC TAC CAG GGC AGC 
tp53_reference AA  A   P   A   P   S   W   P   L    S   S   S   V   P   S   Q   K   T   Y   Q   G   S  
                *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** ***  
 
Splice Sites  
Exon 3 
Exon 4 
Left Primer  










5’ End  
Wildtype  GTGGATCCATTGGAAGGGCAGGCCCACCACCCCGACCCCAACCCCAGCCCCCTAGCAGAGACCTGTGGGAAGCGAAAATTCCATGGGACTGACT 
Mutant        GTGGATCCATTGGAAGGGCAGGCCCACCACCCCGACCCCAACCCCAGCCCCCTAGCAGAGACCTGTGGGAAGCGAAAATTCCATGGGACTGACT  
tp53_reference  GTGGATCCATTGGAAGGGCAGGCCCACCACCCCAACCCCAACCCCAGCCCCCTAGCAGAGACCTGTGGGAAGCGAAAATTCCATGGGACTGACT   
                       ********************************* ************************************************************  
                 
               26  27  28  29  30  31  32   
Wildtype    TTCTGCTCTTGTCTTTCAG A CTT CCT GAA AAC AAC GTT CTG GTAAGGGCAAGGGTTGGGC 
Wildtype AA                                   L   P   E   N   N   V   L 
Mutant     TTCTGCTCTTGTCTTTCAG A CTT CCT GAA AAC AAC GTT CTG GTAAGGGCAAGGGTTGGGC 
Mutant AA                                     L   P   E   N   N   V   L 
tp53_reference    TTCTGCTCTTGTCTTTCAG A CTT CCT GAA AAC AAC GTT CTG GTAAGGGCAAGGGTTGGGC 
tp53_reference AA                             L   P   E   N   N   V   L 
                     ******************* * *** *** *** *** *** *** *** ******************* 
 
Wildtype  TGGGGACCTGGAGG----------------GCTGGGGGGCTGGGGGGCTGAGGACCTGGT 
Mutant     TGGGGACCTGGAGG----------------GCTGGGGGGCTGGGGGGCTGAGGACCTGGT 
tp53_reference    tggggacctggagggctggggacctggagggctggggggctggggggctgAGGACCTGGT  
                  **************                ****************************** 
 
    33  34  35  36  37  38  39  40  41  42  43 
Wildtype    CCTCTGACTGCTCTTTTCACCCATCTACAG TCC CCC TTG CCG TCC CAA GCA ATG GAT GAT TTG 
Wildtype AA                 S   P   L   P   S   Q   A   M   D   D   L                     
Mutant     CCTCTGACTGCTCTTTTCACCCATCTACAG --- --- --- --- TCC CAA GCA ATG GAT GAT TTG 
Mutant AA                                        S   Q   A   M   D   D   L                     
tp53_reference    CCTCTGACTGCTCTTTTCACCCATCTACAG TCC CCC TTG CCG TCC CAA GCA ATG GAT GAT TTG  
tp53_reference AA                 S   P   L   P   S   Q   A   M   D   D   L                     
   ******************************                 *** *** *** *** *** *** ***                  
 
 
   44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64    
Wildtype  ATG CTG TCC CCG GAC GAT ATT GAA CAA TGG TTC ACT GAA GAC CCA GGT CCA GAT GAA GCT CCC  
Wildtype AA   M   L   S   P   D   D   I   E   Q   W   F   T   E   D   P   G   P   D   E   A   P 
Mutant            ATG CTG TCC CCG GAC GAT ATT GAA CAA TGG TTC ACT GAA GAC CCA GGT CCA GAT GAA GCT CCC  
Mutant AA   M   L   S   P   D   D   I   E   Q   W   F   T   E   D   P   G   P   D   E   A   P 
tp53_reference    ATG CTG TCC CCG GAC GAT ATT GAA CAA TGG TTC ACT GAA GAC CCA GGT CCA GAT GAA GCT CCC  
tp53_reference AA  M   L   S   P   D   D   I   E   Q   W   F   T   E   D   P   G   P   D   E   A   P 
                  *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** 
 
 
   65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85   
Wildtype    AGA ATG CCA GAG GCT GCT CCC CGC GTG GCC CCT GCA CCA GCA GCT CCT ACA CCG GCG GCC CCT 
Wildtype AA   R   M   P   E   A   A   P   R   V   A   P   A   P   A   A   P   T   P   A   A   P  
Mutant      AGA ATG CCA GAG GCT GCT CCC CGC GTG GCC CCT GCA CCA GCA GCT CCT ACA CCG GCG GCC CCT 
Mutant AA   R   M   P   E   A   A   P   R   V   A   P   A   P   A   A   P   T   P   A   A   P 
tp53_reference    AGA ATG CCA GAG GCT GCT CCC CCC GTG GCC CCT GCA CCA GCA GCT CCT ACA CCG GCG GCC CCT 
tp53_reference AA  R   M   P   E   A   A   P   P   V   A   P   A   P   A   A   P   T   P   A   A   P 
     *** *** *** *** *** *** *** * * *** *** *** *** *** *** *** *** *** *** *** *** *** 
 
 
   86  87  88  89  90  91  92  93  94  95  96  97  98  99  100 101 102 103 104 105 106    
Wildtype  GCA CCA GCC CCC TCC TGG CCC CTG TCA TCT TCT GTC CCT TCC CAG AAA ACC TAC CAG GGC AGC 
Wildtype AA   A   P   A   P   S   W   P   L    S   S   S   V   P   S   Q   K   T   Y   Q   G   S  
Mutant   GCA CCA GCC CCC TCC TGG CCC CTG TCA TCT TCT GTC CCT TCC CAG AAA ACC TAC CAG GGC AGC 
Mutant AA   A   P   A   P   S   W   P   L    S   S   S   V   P   S   Q   K   T   Y   Q   G   S  
tp53_reference  GCA CCA GCC CCC TCC TGG CCC CTG TCA TCT TCT GTC CCT TCC CAG AAA ACC TAC CAG GGC AGC 
tp53_reference AA  A   P   A   P   S   W   P   L    S   S   S   V   P   S   Q   K   T   Y   Q   G   S  
                *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** ***  
 
Splice Sites  
Exon 3 
Exon 4 
Left Primer  











The most obvious dissimilarity seen between the mutant and the wildtype is the deletion 
at the beginning of exon 4, which consists of 12 nucleotide bases/4 amino acids and which 
includes serine 33. This deletion is only seen in the mutant. Since the deletion is exactly 12 
amino acids long, there is no change in the reading frame. Instead, the p53 protein is shortened 
from 393 to 389 amino acids long. In comparison to the reference sequence, both the mutant and 
wildtype share a few other differences. Near the right primer, there is a G instead of an A. In 
addition, there is a deletion in both the mutant and wildtype cell lines in the intronic sequence 
between exons 3 and 4. Since these changes are in intronic regions, there should be no changes 
to the p53 protein. However, in the exonic region, both the wildtype and mutant share a single 
nucleotide polymorphism (SNP) in codon 72. This SNP leads to conversion of the amino acid 
from proline (CCC) to arginine (CGC). This conversion is important to recognize because 
proline is a neutral, nonpolar, but bulky amino acid while arginine is a basic amino acid. This 
change from neutral to basic can affect the structure of the protein, leading to a possible change 
in function. Recent studies in ovarian cancer demonstrated an association between this 
polymorphism and the risk of cancer development, along with a variation in the patient’s 
response to chemotherapy (Antoun et al., 2018). 
One study suggests that codon 72 as arginine is more effective in inducing apoptosis than 
proline, but states that the reason for this is not fully understood (Olivier, Hollstein & Hainaut, 
2010). All these differences seen in both the wildtype and mutant further emphasize their 
identical genetic backgrounds. The only variation between the wildtype and mutant is the 
deletion in exon 4, suggesting that any significant differences would be caused by our CRISPR-
Cas9 deletion.  
3.2      Protein and Gene Expression Levels in Wildtype and Mutated Cell Lines (Aim 2) 
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After determining that a deletion mutation had occurred in the desired location, the 
molecular impacts, specifically protein and RNA expression, were compared to the wildtype. 
Since the mutants G2C4, G3B2 and G3C11 all showed the same deletion, we decided to focus on 
the G3B2 cell line. Since p53 is regulated at the protein level, we started with examining protein 
level through a western blot analysis. The western showed that the mutant G3B2 had decreased 
protein expression in comparison to the wildtype (Figure 4).  
 
A two sample, equal variance student’s t-test gave a p-value of 0.0001, which was 
considered to be statistically significant when compared to 0.05. Normally, p53 is seen at low 
levels in the cell and is degraded by MDM2. Phosphorylation of p53 activates the protein and 
increases its expression levels. Our mutant, normalized to the wildtype, showed lower 
expression. The deletion encompasses the serine 33 phosphorylation site, allowing for the protein 
to be degraded to lower levels than normal. 
Figure 4: Protein expression under normal conditions of mutant and wildtype compared. A western 
blot analysis of p53 was completed using cell lysates and p53 monoclonal antibody (Novousbio cat. 
no.NB200-103SS), and B-actin monoclonal antibody (Sigma, cat no 5441). A picture of the gel is seen on 
the left. Quantification of the western blot was completed in ImageJ to show band intensity and shown on 
the right. Three different quantification methods of the pixel density completed in ImageJ gave standard 
error and two sample, equal variance student’s t-test gave a p-value of 0.0001. *** indicates p < 0.0005 
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Even though p53 is regulated on the protein level, we did have a 12 nucleotide deletion in 
the DNA. This lead us to examine if there was a predicted change in the secondary RNA 
structure. Visual and free energy differences in the secondary RNA structure would give a 
possible explanation to differences seen in RNA expression. To determine the secondary RNA 
structure, RNAfold was used (2019). This site uses different methods to predict secondary RNA 
structure, however, we decided to focus on the Minimum Free Energy (MFE) method since if 
predicts structures based on lowest value of free energy. From RNAfold, a slight difference is 
seen visually (Figure 5). 
 
There is a slight difference in structure indicated by the arrow in Figure 5. In addition, the 
MFE values for the wildtype and mutant structure was -64.20kcal/mol and -59.30kcal/mol, 
respectively. MFE values can give a prediction of the stability of the RNA, with the lower value 
indicating the more stable RNA structure (Garcia-Martin & Clote, 2015). The wildtype had a 
Figure 5: RNA secondary structure prediction of deletion region. RNAfold, a webserver that predicts 
secondary structures of RNA though minimum free energy(MFE), was used to visually compare the wildtype and 
mutant. The predicted free energy values are also shown for each image.  
 21 
lower MFE value suggesting that it is more stable in comparison to the mutant, which may be 
reflected in RNA levels.  
Since the mutant RNA was predicted to be less stable, we wanted to test to see if there 
was decrease in RNA expression as well. Using RTPCR, RNA expression was seen to be lower 
in the mutant than the wildtype (Figure 6). A two-sample equal variance student's t-test gave a p-
value of 0.011 which is less than 0.05, suggesting a statistically significant difference.  
The decrease in RNA levels is consistent with the hypothesis that the deletion altered the 
RNA structure affecting RNA stability. RNA expression seems to be 10 fold lower while protein 
Figure 6: Normalized RNA expression for wildtype versus mutant cell lines. Following protocol 
provided by BioRad with cyber green fluorescent dye, CT values (number of cycles at which the 
fluorescent signal of the reaction crosses the threshold) were obtained. CT values were normalized to 
reference, GAPDH, and then normalized to the wildtype cell line. Standard error was calculated for 
all replicates. A two sample equal variance student’s t-test was completed giving a p-value of 0.01 
which is less than 0.05 and indicated by the *.  
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expression closer to 4 fold decrease. The greater decrease in RNA could be due to the rate of 
degradation. RNA degrades much faster than protein. In addition, protein half-life can reduce the 
rate of degradation. The removal of serine 33 in p53 suggests a change in stability in both the 
protein and RNA level. Past studies of p53 have been done in different cell lines with large 
nonspecific deletion in the transactivating domain show similar results in protein and RNA levels 
(Zhu et al., 1998; Florijan et al., 2019). These results suggests that our mutation creates a LOF 
mutation in p53. Our study is the first study to report the effects of a deletion region containing 
this serine 33 site in terms of protein and RNA levels. This led us to test if p53 function in both 
cell cycle and apoptosis would be affected with the removal if this site. 
3.3      Growth Rate and Relative Apoptotic Function Comparison Between Wildtype and 
Mutant Cell Lines (Aim 3) 
With the knowledge that our deletion created a LOF mutation, we wanted to compare 
growth rates and relative apoptotic function between the wildtype and mutant. From the results 




Figure 7: Growth rates for mutant versus wildtype. Cell proliferation was measured by plating 100,000 cells per well in a 12 
well plate and were counted at the respected time points. Cell counts were normalized using C1V1=C2V2 and then averaged 
across all replicates. A two-sample equal variance, one-tailed student’s t-test was completed to determine statistical significance. 
The p-value for 24 hours and 48 hours was 0.019 and 0.00053 respectively. * indicates p-value less 0.05, *** indicates p-value less 
than 0.0005.  
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At both 24 and 48 hours, the difference between the wildtype and mutant is statistically 
significant with a p-value of 0.019 and 0.00053 respectively. At 72 hours, we still see that the 
mutant is growing faster than the wildtype but the difference has decreased dramatically with 
overlapping standard errors. By 96 hours, no significant difference in growth rates between the 
two variants could be detected. We suspect that the reason for the slowing growth rates and the 
flip at 96 hours is due to the cells reaching confluency: cells have covered a majority of the well 
surface. We expect that if we continued measuring past 96 hours, we would see the growth rates 
leveling off.  
Overall, our results show that there is a higher growth rate for our mutated cells. This 
matches the definition of cancer as uncontrollable growth. The expectation of cancer cells is to 
grow abnormally fast, which is why most therapies are aimed at all fast growing cells. In normal 
cells, p53 will prevent continuation of the cell cycle with stresses such as DNA damage. The cell 
cycle will only continue once these stresses are removed. However, by mutating p53, we are 
allowing cancer cells to evade the stress removal check point. The removal of this checkpoint 
allows for cells to move through the cell cycle at an abnormal rate that matches high growth 
rates. Our results are similar to past studies of p53 completed in heterogeneous backgrounds that 
show that growth rates are higher in mutants in comparison to wildtypes (Bossi et al., 2006; 
Ventura et al., 2007). For instance, one study showed that when they knocked down mutant p53 
in cancer cells, growth rate and replication rate were seen to decrease. These results suggest that 
mutant p53 increases growth rate and removing it from the cell decreases growth rate. These 
studies demonstrate the importance of p53 in cell growth. However, our study is the first to show 
the solo effect of p53 without any genetic background influence.  
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After completing growth rates, we wanted to test cell apoptotic ability and viability under 
chemotherapy. The standard of care for many cancers is Cisplatin: a platinum based drug that 
damages DNA and inhibits DNA synthesis. Our test for apoptosis was a cell viability assay. The 
overall results of the test showed that the mutant cell line had higher cell viability (Figure 8).  
 
Figure 8: Wildtype versus mutant comparison for cell viability under different treatments of 
Cisplatin. Apoptotic function was tested using a Resazurin based Sigma In Vitro Toxicology Assay Kit. 
Cisplatin, the standard of care for ovarian cancer, was diluted from a stock solution to the following 
concentrations: 1nM, 100nM, 1uM, 10uM, and 50uM. Five replicates per treatment were done and seen 
in standard error. A two-sample equal variance, one-tailed student’s t-test was completed to determine 
statistical significance. The p-value for 1um, 10um and 50um was 0.00065, 0.000038 and 0.000043, 
respectively. *** indicates p-value less than 0.0005 and **** indicates a p-value less than 0.00005. 
 
Higher cell viability indicates more live cells than dead cells. It is also described as 
decreased apoptotic function, meaning that apoptotic pathway is not activated or killing cells. At 
low levels of Cisplatin, we see high cell viability and low apoptotic function. When we increase 
the Cisplatin concentration, cell viability decreases as a result of severe DNA damage. However, 
cell viability is still higher in the mutant despite high levels of Cisplatin. These results are 
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consistent with past studies where p53 mutations decreased apoptotic function and increased cell 
viability (Brown & Wouters, 1999). In addition, our results are consistent with a previous study 
demonstrating the significance of phosphorylation of serine 33 in control of apoptotic function 
(Sanchez-Prieto et al., 2000). However, this past study examined apoptosis in regards to p38 
inhibition while our study is in regards to p53 serine 33 deletion. This region is part of the 
transactivating domain of p53 with other amino acids important for phosphorylation. 
Understanding the complexities of this domain can further explain the importance of p53 
activation. In addition, understanding p53 activation can give a biological explanation of what 
pathway p53 activates in terms of cell cycle or apoptosis. This is the first study for deletions in 
p53 mapping to serine 33 region in a genetically identical background.  
A future study based on the effects of resistance to cisplatin would examine how mutant 
strains compare in terms of protein and RNA levels under chemotherapy. Treating cells with 
cisplatin concentrations, then following up with RT-PCR and western blotting, could give a 
better picture in terms of how cisplatin affects p53.  
3.4      LOF Mutation Created in p53 Gives Predicted Results 
Overall, the results of our study show that a LOF deletion mutation in p53 creates the 
predicted outcomes in our cells. We saw that our mutant had lower protein and RNA expression, 
higher growth rates, and higher cell viability when treated with Cisplatin. Our results are 
generally consistent with previous findings that p53 LOF mutations are functionally significant 
to growth rates and apoptotic function. However, we are the first to directly validate the 
functional importance of the serine 33 phosphorylation site in p53 gene with regards to identical 
genetic background. Mutations in p53 create the defined effects that is seen in cancer. In 
addition, these LOF mutations are of primary significance in creating cancers. The results of our 
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experiments can be clearly attributed to the created mutation without any influence from the 
genetic background.  
However, a limitation of our study was that comparisons were completed only using the 
G3B2 cell line. To further examine the impact of genetic background after a mutation in a CDG, 
comparisons between multiple cell lines is necessary. While only one cell line was used in this 
experiment, we did create other cell lines that had the same deletion. Further comparisons 
between all of the created cell lines can examine how a genetic background can alters itself to 
enhance cancer survival.  
Understanding how cancer evolves over time and its ability to obtain gain of function 
mutations is still being researched. Past studies have shown that cancer arises through mutations 
in CDGs and the impact of genetic background (Bailey et al., 2018). p53, a common CDG, is 
seen to heavily mutated in most cancers (Hsu, 1991). Despite being widely studied, most studies 
in p53 have been done in a heterogeneous background. These results while valuable, ignore the 
effect that genetic background in oncogenesis. A recent study demonstrated that functionally 
significant mutations in genetic background that occur after major mutations in CDGs can 
impact how cancer develops (Gerstung et al., 2020). The created mutant cell lines from this study 
sets up an ideal experimental setting to test how genetic background can influence cancer 
progression and evolution. The next steps are to allow for the cell lines to continue growing for 
over a year, then examine protein and RNA levels as well as growth rates and apoptotic function 
to determine how genetic background impacted the cells. The hope is that the genetic 
background will mutate to give cancer gain of function abilities. Better understanding of cancer 




CHAPTER 4.  CONCLUSIONS 
Our experiment using CRISPR-Cas9 created a LOF deletion mutation in exon 4 of p53. 
Lower protein and RNA expression along with higher growth and lower apoptotic function was 
seen in the mutant cell line. Our results indicate LOF mutations mapping to CDGs such as p53 
are of primary functional significance to cancer onset and progression. In addition, all the results 
of our experiment were completed in a genetically identical background, ensuring that changes 
are solely because of the created mutation.  
However, recent genomic studies indicate that functionally significant changes in genetic 
backgrounds may arise subsequently to mutations in CDGs that further enhance cancer 
development. The recent paper by Gerstung et al. suggests that genetic background can undergo 
mutations that will lead to overall increased genomic stability in cells (2020). We believe that we 
have created an ideal experimental system for future studies on the evolution of secondary 
mutations (genetic background) occurring subsequent to an initiating mutation in a major cancer 
driver gene. By monitoring subsequent changes in genetic background in this strain over time, 
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